Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | TP53 | P04637 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | THRB | P10828 | 2/20 | 0.81 |
| ▸ | MTOR | P42345 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | ENPP3 | O14638 | 7/20 | 0.69 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030662 | 0.92 | MAPT (0.86) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL3026202 | 0.85 | MTOR (1.00) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL3026147 | 0.84 | MAPT (0.68) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL23493840 | 0.83 | MAPT (1.00) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL31307834 | 0.83 | MAPT (1.00) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL3028283 | 0.83 | MAPT (0.67) | KMT2AMAPTTP53SMN1; SMN2THRB | |
| SCHEMBL22388435 | 0.82 | GPR174 (1.00) | KMT2AMAPTTP53THRBPOLB | |
| SCHEMBL15077996 | 0.76 | GPR174 (1.00) | KMT2AMAPTTP53THRBPOLB | |
| SCHEMBL23493944 | 0.76 | MAPT (1.00) | KMT2AMAPTTP53SMN1; SMN2MTOR | |
| SCHEMBL3027717 | 0.75 | ENPP3 (0.76) | KMT2AMAPTTP53SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9316633-B2 | Methods for identifying inhibitors of solute transporters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-19 | — | — | US | disclosed |
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | SLC2A1, SLC2A3, SLC2A8 | KMT2A 4412/4885MAPT 1849/4885TP53 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.